# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angi...
- SEC Filing
JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...
HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.
Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $12 price target.
BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by...